NEW YORK, Nov. 22, 2024 /PRNewswire/ — Report on how AI is redefining market landscape – The global ewing’s sarcoma treatment market size is estimated to grow by USD 205.09 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 6.26% during the forecast period. Growing awareness about and funding for ewings sarcoma is driving market growth, with a trend towards emergence of regenerative therapies. However, lack of approved therapies for ewings sarcoma poses a challenge.Key market players include Actiza Pharmaceutical Pvt. Ltd., Advantech Co. Ltd., Amneal Pharmaceuticals Inc., Baxter International Inc., Bristol Myers Squibb Co., Cellectar Biosciences Inc., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Fresenius Kabi AG, GlaxoSmithKline Plc, Gradalis Inc., Johnson and Johnson, LGM Pharma LLC, Merck and Co. Inc., Novartis AG, Ocean pharmaceutical, Pfizer Inc., PharmaMar SA, Salvavidas, and UPMC Hillman Cancer Center.
AI-Powered Market Evolution Insights. Our comprehensive market report ready with the latest trends, growth opportunities, and strategic analysis- View Free Sample Report PDF
Forecast period | 2024-2028 |
Base Year | 2023 |
Historic Data | 2018 – 2022 |
Segment Covered | End-user (Hospitals, Specialty clinics, and Others), Type (Combination therapy and Monotherapy), and Geography (North America, Europe, Asia, and Rest of World (ROW)) |
Region Covered | North America, Europe, Asia, and Rest of World (ROW) |
Key companies profiled | Actiza Pharmaceutical Pvt. Ltd., Advantech Co. Ltd., Amneal Pharmaceuticals Inc., Baxter International Inc., Bristol Myers Squibb Co., Cellectar Biosciences Inc., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Fresenius Kabi AG, GlaxoSmithKline Plc, Gradalis Inc., Johnson and Johnson, LGM Pharma LLC, Merck and Co. Inc., Novartis AG, Ocean pharmaceutical, Pfizer Inc., PharmaMar SA, Salvavidas, and UPMC Hillman Cancer Center |
Key Market Trends Fueling Growth
Ewing sarcoma, a type of bone cancer affecting children and adolescents, is characterized by the activation of the EWS gene on chromosomes 11 and 22. The disease primarily affects the legs, pelvis, chest, and abdomen, causing symptoms like lump formation, fever, bone pain, broken bones, weight loss, paralysis, and bladder loss. Treatment typically involves a combination of chemotherapy drugs such as Vincristine, Cyclophosphamide, Doxorubicin, Etoposide, Ifosfamide, and Dactinomycin. Technological advancements have led to the development of pipeline drugs like CDK inhibitors and Regenerative Therapies. Government organizations and healthcare providers continue to invest in disease diagnosis and healthcare spending for approved treatments like Gene Therapy and Disease Diagnosis. Companies like Zydus Cadila and Seqens are leading in this field. Surgery, radiation therapy, and multidrug chemotherapy are common treatment methods. Surgical procedures are performed in hospitals, clinics, and nursing homes, with medical tourism and digital services playing a role in accessibility. The mortality rate for Ewing sarcoma is high, emphasizing the need for continued research and innovation. Symptoms may also affect vital organs like the lungs, heart, kidneys, and skin tissue.
The Ewing’s sarcoma treatment market has witnessed notable progress in addressing metastatic and recurrent Ewing’s sarcoma cases. A cutting-edge approach gaining attention is regenerative medicine, specifically gene therapy. In this method, the patient’s mutated gene is extracted and altered in a lab before being reintroduced. The new gene replaces the faulty one. Although no approved gene therapies exist for Ewing’s sarcoma, numerous pharmaceutical companies are researching and developing these treatments to combat metastatic and recurrent tumors.
Insights on how AI is driving innovation, efficiency, and market growth- Request Sample!
Market Challenges
- Ewing sarcoma, a type of bone cancer affecting children and adolescents, poses significant challenges in treatment due to its aggressive nature and complex genetic makeup. The primary treatment involves multidrug chemotherapy using Vincristine, Cyclophosphamide, Doxorubicin, Etoposide, Ifosfamide, and Dactinomycin, which target the activation of the EWS gene on chromosomes 11 and 22. However, the disease’s incidence and symptoms, including lump formation, fever, bone pain, broken bones, weight loss, paralysis, and bladder loss, necessitate continuous research and technological advancements. Government organizations and healthcare providers invest heavily in pipeline drugs, such as CDK inhibitors and Regenerative Therapies, to improve disease diagnosis and treatment. Companies like Zydus Cadila and Seqens are developing new therapies, including Gene Therapy and Anti-stathmin therapy, to address recurrent Ewing tissue. The treatment landscape includes surgery, radiation therapy, and chemotherapy in hospitals, clinics, nursing homes, and through medical tourism. Symptoms and vital organ involvement, such as the lungs, heart, kidneys, and skin tissue, require specialized care. The mortality rate underscores the need for continued research and investment in this area. Healthcare spending on Ewing sarcoma treatment is substantial, with diagnostic services, digital services, and surgical procedures being key components. The challenges in treating Ewing sarcoma necessitate a collaborative effort from all stakeholders to improve patient outcomes and quality of life.
- Ewing’s sarcoma is a severe bone and soft tissue cancer primarily affecting adolescents and young adults. The primary tumor is treated with either surgery or radiation, depending on the feasibility of surgical resection. Due to the high risk of metastasis, even in localized cases, chemotherapy is also administered to eliminate microscopic tumors. Chemotherapeutic agents like vincristine, doxorubicin, and cyclophosphamide are commonly used. Although most patients with initially localized Ewing’s sarcoma survive long-term, relapse remains a significant issue. There is currently no standard approach to treating relapsed patients.
Insights into how AI is reshaping industries and driving growth- Download a Sample Report
Segment Overview
This ewing’s sarcoma treatment market report extensively covers market segmentation by
- End-user
- 1.1 Hospitals
- 1.2 Specialty clinics
- 1.3 Others
- Type
- 2.1 Combination therapy
- 2.2 Monotherapy
- Geography
- 3.1 North America
- 3.2 Europe
- 3.3 Asia
- 3.4 Rest of World (ROW)
1.1 Hospitals- Hospitals, particularly large and medium-sized institutions, play a significant role in driving the growth of the Ewing’s sarcoma treatment market. These hospitals, with over 500 beds, are key end-users due to their high patient volume and purchasing power. They procure therapeutics in large quantities, enabling manufacturers to expand their product reach and enhance brand image. With advanced medical infrastructure and a growing number of emergency department visits due to the increasing incidence of Ewing’s sarcoma, sales of treatment therapeutics are expected to rise in these hospitals. Medium-sized hospitals, with around 200-300 beds, also contribute to market expansion. Despite their limited budgets, they engage closely with various stakeholders and have an increasing number of patients, leading to increased demand for Ewing’s sarcoma treatment therapeutics.
Download complimentary Sample Report to gain insights into AI’s impact on market dynamics, emerging trends, and future opportunities- including forecast (2024-2028) and historic data (2018 – 2022)
Research Analysis
Ewing sarcoma is a rare and aggressive type of bone cancer that primarily affects children and young adults. It is characterized by the uncontrolled growth of cells in the soft tissues surrounding the bones, often found in the legs, pelvis, chest, and abdomen. The exact cause of Ewing sarcoma is unknown, but it is linked to genetic changes in the EWS gene on chromosomes 11 and 22. The primary treatment for Ewing sarcoma is chemotherapy using drugs such as Vincristine, Cyclophosphamide, Doxorubicin, Etoposide, and Infoposide, as well as Dactinomycin and CDK inhibitors. These drugs target the genetic material and chromosomes of the cancer cells, damaging their ability to divide and grow. The treatment can affect vital organs like the lungs, heart, kidneys, and skin tissue, and may also impact the bone marrow, which can increase the risk of infection and anemia. Age can also be a factor in treatment, as older patients may have different treatment options due to the increased risk of complications. The thigh is a common site for Ewing sarcoma in the legs, and the disease can also occur in the limbs and other bones in the body.
Market Research Overview
Ewing sarcoma is a rare and aggressive type of bone cancer that affects children and adolescents, typically appearing in the legs, pelvis, chest, and abdomen. The disease is caused by the activation of the EWS gene on chromosomes 11 and 22, leading to the uncontrolled growth of cells. The primary treatment for Ewing sarcoma is multidrug chemotherapy using agents like Vincristine, Cyclophosphamide, Doxorubicin, Etoposide, Ifosfamide, and Dactinomycin. These drugs work by damaging the genetic material of the cancer cells. Technological advancements have led to the development of pipeline drugs and diagnostics, including CDK inhibitors and Regenerative Therapies such as Gene Therapy and Disease Diagnosis. Healthcare spending on Ewing sarcoma treatment is significant, with approved treatments including Surgery, Radiation therapy, and Chemotherapy. Symptoms of Ewing sarcoma include lump formation, fever, bone pain, broken bones, weight loss, paralysis, and bladder loss. Treatment options depend on the location and severity of the disease, with surgical procedures and medical tourism also playing a role. Mortality rate is high for recurrent Ewing tissue, with organizations like Gradalis and Seqens offering anti-stathmin therapy as a potential treatment. The disease can affect various bones, including the thigh, pelvis, and limbs, as well as vital organs such as the lungs, heart, kidneys, and skin tissue. Age is a significant factor in the diagnosis and treatment of Ewing sarcoma, with hospitals and clinics providing essential services to those affected. Nursing homes and digital services also play a role in the care of patients. Overall, the Ewing sarcoma treatment market is continually evolving, with ongoing research and development efforts aimed at improving outcomes for patients.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- End-user
- Hospitals
- Specialty Clinics
- Others
- Combination Therapy
- Monotherapy
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
